Lite Strategy (LITS) Other Working Capital Changes (2010 - 2026)
Lite Strategy (LITS) posted Other Working Capital Changes of -$334000.0 for Q1 2026, up 31.28% on a QoQ basis from -$486000.0 in Q4 2025, and up 1.47% year-over-year from -$329145.3 in Q1 2025.
Analysis
Lite Strategy (LITS) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Lite Strategy has reported Other Working Capital Changes for 17 years, with the latest figure at -$334000.0 in Q1 2026.
- On a quarterly basis, Other Working Capital Changes rose 1.47% year-over-year to -$334000.0 in Q1 2026; TTM through Mar 2026 was $452000.0, a 103.9% increase from a year earlier, with the FY2025 full-year figure at -$2.2 million, up 84.21% from the prior year.
- Other Working Capital Changes was -$334000.0 for Q1 2026 at Lite Strategy, up from -$486000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $78.4 million in Q2 2020, with the low at -$64.9 million in Q3 2023.
- Average Other Working Capital Changes over 5 years is -$1.0 million, with a median of -$1.3 million recorded in 2022.
- The largest YoY upside for Other Working Capital Changes was 650.0% in 2022 against a maximum downside of 1397.14% in 2022.
- Over 5 years, Other Working Capital Changes stood at $429000.0 in 2022, then sank by 139.86% to -$171000.0 in 2023, then decreased by 13.45% to -$194000.0 in 2024, then plunged by 150.52% to -$486000.0 in 2025, then surged by 31.28% to -$334000.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$334000.0 (Q1 2026), -$486000.0 (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -334,000.00 |
| Mar 31, 2026 | -334,000.00 |
| Dec 31, 2025 | -486,000.00 |
| Dec 31, 2025 | -486,000.00 |
| Sep 30, 2025 | 1.31 Mn |
| Sep 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | -33,000.00 |
| Jun 30, 2025 | -33,000.00 |
| Mar 31, 2025 | -339,000.00 |
| Mar 31, 2025 | -339,000.00 |
| Dec 31, 2024 | -194,000.00 |
| Dec 31, 2024 | -194,000.00 |
| Sep 30, 2024 | -1.58 Mn |
| Sep 30, 2024 | -1.58 Mn |
| Jun 30, 2024 | -9.47 Mn |
| Jun 30, 2024 | -9.47 Mn |
| Mar 31, 2024 | -3.44 Mn |
| Mar 31, 2024 | -3.44 Mn |
| Dec 31, 2023 | -171,000.00 |
| Dec 31, 2023 | -171,000.00 |